Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Prenetics Q3 2026 slides: revenue beats, but growth spend sinks stock

Prenetics Global Limited announced its Q3 2026 results on November 18, 2026, with revenue exceeding expectations but causing a significant 37-42.5% drop in stock price. Shareholders reacted negatively to the company's decision to increase growth spending, which led to a much wider loss outlook for the second half of 2026. Despite the revenue growth, the adjusted EBITDA losses for the second half of 2026 are now projected to be between $30 and $35 million, a stark contrast to the previous range of $8 and $12 million.

The company's IM8 wellness brand generated $62.9 million in revenue for Q3 2026, representing a 39.8% increase sequentially and a 3.7x increase year-over-year. This brand accounts for the majority of the company's revenue. While the company reported positive adjusted free cash flow of $4.1 million in Q3, this figure includes $31.6 million of net funding from General Catalyst's Customer Value Fund facility.

The company's gross margin remained at 64%, and contribution profit reached $30.6 million, reflecting a 48% margin. Management's growth investment strategy is backed by validated unit economics, with General Catalyst's cohort test showing $1.68 returned per dollar of acquisition marketing. The company's earliest customer cohorts have demonstrated substantial long-term value, with the Q1 2025 cohort returning 4.06x gross profit per acquisition dollar in less than two years. Despite the rapid growth, IM8 holds just 0.14% share of the global dietary supplements category.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

More from Wednesday 18 November →